Related Experiment Videos
[Ezetimibe--pharmacokinetics and therapeutics].
Renata G Araújo1, Antonio Casella Filho, Antonio Carlos P Chagas
1Unidade Clínica de Aterosclerose, Instituto do Coração, HCFMUSP.
Arquivos Brasileiros De Cardiologia
|January 10, 2006
Summary
Ezetimibe inhibits cholesterol absorption in the gut by targeting specific enzymes. It is well-tolerated and effective, especially when combined with statins for significant lipid profile improvements.
Area of Science:
- Pharmacology
- Gastroenterology
- Metabolic Diseases
Context:
- Ezetimibe is a cholesterol absorption inhibitor.
- It undergoes liver glucuronidation and acts on enterocytes.
- Its prolonged half-life allows once-daily dosing.
Purpose:
- To elucidate the mechanism of action of ezetimibe.
- To describe its pharmacokinetic and safety profile.
- To evaluate its efficacy in lipid management.
Summary:
- Ezetimibe reduces cholesterol absorption by inhibiting gut cholesterol transporters.
- It is primarily excreted via feces.
- Monotherapy yields modest LDL-c reduction, while combination with statins shows significant lipid-lowering effects.
Impact:
- Ezetimibe offers a well-tolerated option for cholesterol management.
- Combination therapy with statins provides enhanced lipid profile modification.
- This contributes to the therapeutic arsenal against hyperlipidemia.